GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Parabilis Medicines, Inc. Common Stock PBLS · USD

US listing · 🇺🇸 United States

Compare

30.37

+6.45%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Parabilis Medicines, Inc. Common Stock

Its shares trade under the ticker PBLS. It has been listed since 10 June 2026.

Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Listed since
10 Jun 2026
Head office
30 ACORN PARK DRIVE, CAMBRIDGE, MA, 02140
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
<br>Emerging growth company

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Developing helical peptide therapeutics for undruggable targets using Helicon platform
  • Lead clinical program FOG-001 targets beta-catenin for cancer treatment
  • Integrating AI and data science into drug discovery and clinical strategy

Weaknesses

  • Clinical-stage company with no approved products yet
  • Limited pipeline beyond FOG-001 in oncology focus
  • Dependent on successful clinical trials for FOG-001

Opportunities

  • Expanding helical peptide therapeutics to new disease areas
  • Growing demand for targeted cancer treatments in oncology
  • Collaborating with clinical research organizations in healthcare industry

Threats

  • Competition from established biopharmaceutical companies
  • Regulatory hurdles in clinical trial approvals
  • Market volatility affecting biotech stock performance

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.